Skip to main content
Monday, November 16, 2026Nov 16

Times Opinion: An erratic FDA is a threat to innovation

Photo by Michael Sohn - Pool via Getty Images/TNS / Three vials of the Moderna COVID-19 vaccine are pictured on Feb. 17, 2021.
Photo by Michael Sohn - Pool via Getty Images/TNS / Three vials of the Moderna COVID-19 vaccine are pictured on Feb. 17, 2021.

Few corporate cautionary tales are as vivid as the rise and fall of Moderna Inc.

During the pandemic, the company’s mRNA vaccine was approved and distributed in record time, saving millions of lives and turning a once-obscure startup into a $200 billion behemoth.

Now Moderna is in a tight spot: Hundreds of millions of dollars in grants for mRNA shots were rescinded last year, one of the company’s newest products is in limbo, and its market value has dwindled to about a tenth of its pandemic-era high.

What happened? In large part: politics.

As the COVID-19 outbreak eased, demand for vaccines inevitably fell. Yet White House officials also changed their tune. Out went the optimism about mRNA and in came wild theories that this miraculous, Nobel Prize-winning technology wasn’t safe. By way of defending this posture, the country’s top drug official recently said Moderna and its peers “can fund their own research.”